Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Regulatory antibody strategy vs. allergies

Regulatory antibody strategy vs. allergies

Allergene Inc., which is developing regulatory antibodies to treat allergic diseases, told BioCentury that it is looking to raise a second venture round of about $5 million from either venture

Read the full 355 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE